Ebola vaccine // Sanofi & Genzyme // Apogenix China // Personalised Cancer Medicines // iPS Cells //
All articles provided by LABIOTECH.EU
In outbreak situations such as the Ebola crisis, vaccines play an essential role that was largely needed during the 2014 health emergency, especially when the plague reached the First World. To ensure preparedness against Ebola, now and in the future, companies have been rushing to develop vaccines against this disease ... MORE
There seems to be a tendency towards revolution amongst Sanofi’s CEOs. Olivier Brandicourt, Managing director of the French drugmaker since his €4.1M golden handshake with the company, has come up with a restructuration plan that will reduce Sanofi’s business units from seven to five. The French businessman expects this reorganization … MORE
Apogenix wants to enter the world’s second biggest pharma market. Its lead candidate APG101 was just licensed by CANbridge Life Sciences to treat patients suffering from glioblastomas in China, Macao and Hong Kong. Last year, during our South Germany tour, we payed a visit to Heidelberg-based Apogenix. The company is … MORE
Personalized Cancer medicines are becoming reality thanks to AstraZeneca and Qiagen’s newly approved combo
A new success for personalized medicines against cancer! AstraZeneca and Qiagen’s collaboration has achieved a major milestone after receiving the FDA’s approval of Iressa, a first-line treatment for a common form of lung cancer. The drug candidate is paired with Qiagen’s therascreen EGRF test as a companion diagnostic test. … MORE
When the Nobel Prize-winning Dr. Shinya Yamanaka succeeded to generate induced pluripotent cells (iPS cells) from specialized adult cells, the field of stem cells was completely revolutionized. Since Yamanaka’s paper on adult mouse fibroblasts back in 2006, scientists have been able to perform cellular reprogramming, but the process still isn’t … MORE
July 18th, 2015
Looking for special service?
Don't spend time on search!
Get applications from providers For Free